CM118, a new anti lung cancer drug of Shanghai Zaixin medicine, has completed preclinical study

According to Dr Yu Ke, vice general manager of Zaixin medicine, Professor of Fudan University School of medicine and famous new drug R & D expert of "national thousand talents plan", CM118 project is one of a series of new drug projects designed by Dr Liang Congxin, chief scientist and master of new drug design and R & D of the company The pre clinical research results just completed show that CM118 is likely to be another internationally leading new anti-cancer drug
CM118 is a kind of selective met kinase and alk kinase inhibitor It is designed directly for the new anti lung cancer drug clozatinib, which has been listed by Pfizer company in the United States On the basis of the advantages of the effectiveness and low toxicity of clozatinib to ALK lung cancer patients, CM118 can further overcome the shortcomings of drug interaction of clozatinib and expand this new type of anti-cancer drug The possibility of combination with other anticancer drugs can greatly improve the therapeutic effect The results of preclinical trials show that CM118 is likely to achieve the expected design goals At the same time, met kinase is directly related to tumor growth, metastasis and diffusion (for example, bone metastasis that causes extreme pain in patients with advanced cancer) It is also an important drug resistance mechanism of high-end anticancer drugs such as erlotinib, gefitinib and Avastin Clinical trials of met kinase inhibitors have proved that it has a good effect on non-small cell lung cancer (combined with erlotinib), prostate cancer, breast cancer, ovarian cancer (combined with VEGFR inhibitors) During the preclinical research of CM118, cro companies for pharmaceutical R & D outsourcing founded by returned overseas students, such as Sandia Pharmaceutical Technology Co., Ltd., Shaoyuan Chemical Technology Co., Ltd and medixi Biomedical Technology Co., Ltd., which are also located in Zhangjiang High Tech Park, Shanghai, and Fudan University School of pharmacy provide major R & D outsourcing services Dingjian investment fund's investment in new medicine ensured the successful completion of CM118 preclinical research Zhangjiang biomedical base also provided important support for CM118 project Dr Tang Ming, chairman and general manager of Zaixin pharmaceutical, said that at present, the international first-class good drugs, which often cost hundreds of thousands or even hundreds of thousands of yuan a year in the Chinese market, are far from our Chinese people For example, Pfizer's listed sunitinib (sotan) and clozatinib (secore) in China cost hundreds of thousands of yuan each year, which is beyond the reach of most Chinese patients Many cancer patients have to give up treatment The purpose of our research and development of CM082 and CM118, which are world-class new drugs in China, is not only to fill the gaps in domestic science and technology and industry, but also to provide affordable and good drugs for Chinese people We strive to complete the clinical research of these new drug projects as soon as possible to benefit the Chinese people